摘要
目的观察氯化锶(^(89)Sr)联合唑来膦酸对非小细胞肺癌(non-small cell lung cancer,NSCLC)骨转移患者的疗效,为此类患者的用药方案提供依据。方法选取2021年5月至2023年5月南阳市中心医院收治的116例出现骨转移的NSCLC患者,随机分为^(89)Sr组与联合组各58例,^(89)Sr组单独应用^(89)Sr治疗,联合组给予^(89)Sr联合唑来膦酸治疗,比较两组骨转移病灶治疗有效率、疼痛程度、血液学毒副作用指标与不良反应情况、治疗前后生活质量状况。结果联合组总有效率(60.34%)高于^(89)Sr组(20.69%)(P<0.05);治疗后联合组疼痛分级0级(15.52%)、Ⅰ级(48.28%)比例高于^(89)Sr组(0.00%、20.69%),疼痛分级Ⅱ级(31.03%)、Ⅲ级(5.17%)比例低于^(89)Sr组(51.72%、27.59%)(P<0.05);治疗后联合组白细胞、血小板分别为(3.63±0.91)×10^(9)/L、(121.37±24.82)×10^(9)/L,低于^(89)Sr组的(4.12±0.83)×10^(9)/L、(136.83±18.74)×10^(9)/L,差异有统计学意义(P<0.05);联合组不良反应发生率为12.07%,与对照组的20.69%差异无统计学意义(P>0.05);治疗后联合组躯体功能、角色功能、认知功能、情感功能、社会功能评分分别为(71.58±8.82)分、(68.76±6.78)分、(64.02±5.22)分、(61.74±6.04)分、(58.76±6.96)分,均高于^(89)Sr组的(57.73±5.98)分、(58.78±6.35)分、(53.45±5.81)分、(56.72±5.26)分、(52.27±5.63),分差异有统计学意义(P<0.05)。结论^(89)Sr联合唑来膦酸可提高NSCLC骨转移病灶的治疗有效率,明显改善疼痛症状,降低治疗毒副作用,提高患者生活质量。
Objective To observate of the therapeutic effect of strontium chloride(89Sr)combined with zoledronic acid on non-small cell lung cancer(NSCLC)patients with bone metastases,providing a basis for the medication regimen of such patients.Methods Totally 116 NSCLC patients with bone metastases treated in the Nanyang Central Hospital from May 2021 to May 2023 were randomly divided into^(89)Sr group and combined group,with 58 patients in each group.^(89)Sr group was treated with^(89)Sr alone,and the combined group was treated with^(89)Sr combined with zoledronic acid.The effective rate,pain degree,hematological toxicities and side effects,quality of life before and after treatment were compared between the two groups.Results The total effective rate of combination group(60.34%)was higher than that of^(89)Sr group(20.69%)(P<0.05).After treatment,the percentages of pain grade 0(15.52%)and I(48.28%)in combination group were higher than those in^(89)Sr group(0.00%,20.69%),and the percentages of pain gradeⅡ(31.03%)andⅢ(5.17%)in combination group were lower than those in^(89)Sr group(51.72%,27.59%)(P<0.05).After treatment,the WBC and platelet values in combination group were(3.63±0.91)×10^(9)/L and(121.37±24.82)×10^(9)/L,respectively,which were lower than those in^(89)Sr group(4.12±0.83)×10^(9)/L and(136.83±18.74)×10^(9)/L(P<0.05).The incidence of adverse reactions in combination group was 12.07%,which was not significantly different from 20.69%in control group(P>0.05).After treatment,the scores of physical function,role function,cognitive function,emotional function and social function in the combined group were(71.58±8.82)scores,(68.76±6.78)scores,(64.02±5.22)scores,(61.74±6.04)scores and(58.76±6.96)scores,respectively.They were higher than those in^(89)Sr group(57.73±5.98),(58.78±6.35),(53.45±5.81),(56.72±5.26)and(52.27±5.63)(P<0.05).Conclusion^(89)Sr combined with zoledronic acid can improve the treatment efficiency of NSCLC bone metastases,significantly improve pain symptoms,reduce the side effects
作者
王云春
任中海
WANG Yun-chun;REN Zhong-hai(Department of Western Medicine,Nanyang Central Hospital,Nanyang,Henan 473000,China;Department of Oncology,Nanyang Central Hospital,Nanyang,Henan 473000,China)
出处
《医药论坛杂志》
2024年第16期1764-1767,1772,共5页
Journal of Medical Forum
基金
河南省医学科技攻关计划联合共建项目(LHGJ20191450)。
关键词
氯化锶
唑来膦酸
非小细胞肺癌
骨转移
疼痛
临床疗效
不良反应
Strontium chloride
Zoledronic acid
Non-small-cell lung cancer
Bone metastasis
Pain
Treament outcome
Adverse reaction
